Serotonin and 5-hydroxytryptophan on blood pressure and renal blood flow in anesthetized rats.

The effects of exogenous (injected) serotonin on mean blood pressure and renal blood flow in male Sprague-Dawley rats were compared with the effects of enhanced endogenous serotonin, accomplished by injections of 5-hydroxytryptophan (5-HTP). Responses were evaluated with and without carbidopa, which blocks peripheral conversion of 5-HTP to serotonin, and with and without indomethacin to assess the contribution of prostanoids. Both serotonin (0.25-1.0 micrograms) and 5-HTP (50-200 micrograms) decreased blood pressure and renal blood flow and increased renal vascular resistance in dose-dependent fashion. Hypotensive responses with both agents were greater after arterial injections into the aortic arch than after intravenous injections (into the jugular vein). Carbidopa had no significant effects on responses to serotonin but ablated the ability of 5-HTP to increase renal vascular resistance and decrease renal blood flow. Carbidopa did not alter the hypotensive action of 5-HTP. Indomethacin had no significant effect on responses to serotonin or 5-HTP. These results support a direct renal vasoconstrictor effect for exogenous and endogenously formed serotonin and a hypotensive effect probably arising in the central nervous system.

[1]  C. Orlandi,et al.  Serotonin and the renal blood supply: role of prostaglandins and the 5HT-2 receptor. , 1986, Kidney international.

[2]  T. Brewer,et al.  Formation of biogenic amines by isolated kidneys of spontaneously hypertensive rats. , 1986, Life sciences.

[3]  R. Ardaillou,et al.  Prostaglandins and other arachidonic acid metabolites in the kidney. , 1986, Kidney international.

[4]  C. Stier,et al.  Formation of Serotonin by Rat Kidneys in Vivo , 1985, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[5]  R. Cohen,et al.  Serotonin and arterial vessels. , 1984, Journal of cardiovascular pharmacology.

[6]  C. Stier,et al.  Serotonin formation in nonblood-perfused rat kidneys. , 1984, The Journal of pharmacology and experimental therapeutics.

[7]  H. Echizen,et al.  Long-term infusion of L-5-hydroxytryptophan increases brain serotonin turnover and decreases blood pressure in normotensive rats. , 1982, The Journal of pharmacology and experimental therapeutics.

[8]  C. N. Gillis,et al.  The fate of circulating amines within the pulmonary circulation. , 1982, Annual review of physiology.

[9]  R. Horton,et al.  Prostaglandins, renal function and vascular regulation. , 1981, The Medical clinics of North America.

[10]  M. Krstić,et al.  Analysis of cardiovascular responses to central administration of 5-hydroxytryptamine in rats , 1980, Neuropharmacology.

[11]  W. Lovenberg,et al.  Review of the Role of the Central Serotonergic Neuronal System in Blood Pressure Regulation , 1980, Hypertension.

[12]  R. Roman,et al.  Inhibition of Renal Prostaglandin Synthesis and Metabolism by Indomethacin in Rats , 1978, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[13]  R. Roman,et al.  Renal effect of prostaglandin synthetase inhibition in rats: micropuncture studies. , 1978, The American journal of physiology.

[14]  K. Malik,et al.  Prostaglandins as determinants of vascular reactivity. , 1976, Federation proceedings.

[15]  G. J. Blackwell,et al.  Genetic hypertension in rats is accompanied by a defect in renal prostaglandin catabolism , 1976, Nature.

[16]  S. Gershon,et al.  Centrally-mediated carcdiovascular responses to 5-HT. , 1975, Life sciences.

[17]  C. W. Gottschalk,et al.  Autoregulation of blood flow in the rat kidney. , 1975, The American journal of physiology.

[18]  A. Junod Uptake, metabolism and efflux of 14 C-5-hydroxytryptamine in isolated perfused rat lungs. , 1972, The Journal of pharmacology and experimental therapeutics.

[19]  V. J. Lotti,et al.  Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors. , 1970, The Journal of pharmacology and experimental therapeutics.

[20]  I. Page Serotonin (5-hydroxytryptamine); the last four years. , 1958, Physiological reviews.

[21]  I. Page Serotonin (5-hydroxytryptamine). , 1954, Physiological reviews.